Related Experiment Video
Updated: Jun 19, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Individualized antiplatelet therapy: what can a clinical score contribute?
1Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Universitätsklinikum der Eberhard-Karls-Universität Tübingen, Tübingen, Germany. tobias.geisler@med.uni-tuebingen.de
Insights
Ensuring antiplatelet drug effectiveness is vital for coronary artery disease patients. Personalized therapy, guided by risk assessment, can improve outcomes by addressing variable patient responses and reducing ischemic events.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Risk Assessment
Background:
- Antiplatelet therapy is crucial for patients with coronary artery disease undergoing interventions.
- Patient response to oral antiplatelet drugs is highly variable, influenced by multiple mechanisms.
- High residual platelet aggregability (RPA) despite therapy is linked to recurrent ischemic events after percutaneous coronary intervention (PCI).
Purpose of the Study:
- To discuss strategies for identifying patients who may benefit from personalized antiplatelet therapy.
- To explore risk assessment methods for antiplatelet drug responsiveness.
- To evaluate approaches for optimizing cardiovascular outcomes while minimizing bleeding risk.
Main Methods:
- Literature review on risk assessment for antiplatelet drug responsiveness.
- Discussion of therapeutic strategies including dose adjustment and novel P2Y12 inhibitors.
- Exploration of clinical risk scores for patient stratification.
Main Results:
- Variable patient response to antiplatelet therapy poses a significant clinical challenge.
- High RPA is associated with an increased risk of ischemic events post-PCI.
- Personalized antiplatelet strategies may improve outcomes in non-responsive patients.
Conclusions:
- Individualizing antiplatelet therapy is essential for optimal patient care.
- Risk stratification tools are needed to identify patients requiring tailored treatment.
- Balancing efficacy and bleeding risk is key in personalized antiplatelet strategies.
Abstract:
Safeguarding of antiplatelet drug efficacy represents a cornerstone for the optimal treatment of patients with symptomatic coronary artery disease requiring coronary interventions. This means a challenge to modern cardiology since there has been cumulative evidence, that response to common oral antiplatelet therapy is a highly variable phenomenon underlying various mechanisms. It is known, that particular risk groups exhibit a high residual platelet aggregability (RPA) despite conventional antiplatelet therapy. Additionally, a relevant association between high RPA and recurrent ischaemic events after PCI exists. Individualization of antiplatelet therapy by dose increase or alternative application of novel P2Y12-receptor antagonists might lead to improved cardiovascular outcome in patients with poor responsiveness to conventional antiplatelet therapy. Identification of risk patients who might benefit from tailored therapy by increased net benefit without excess of major bleedings means a challenge. Clinical risk scores might help in the process of risk stratification and therapeutic decision. Subsequently, literature on risk assessment for antiplatelet drug responsiveness and different strategies will be discussed to identify patients who might benefit from personalized antiplatelet strategies.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Atherosclerosis III: Management
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...